# HEDIS<sup>®</sup> Behavioral Health 2021

# **Documentation and Coding Guidelines**

**Reproduced with permission from HEDIS Measurement Year 2020 and Measurement Year 2021, Volume 2:** Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS<sup>®</sup> is a registered trademark of the National Committee for Quality Assurance (NCQA). To purchase copies of this publication, contact NCQA Customer Support at **1-888-275-7585** or visit <u>www.ncqa.org/publications</u>.

# EFFECTIVENESS OF CARE: BEHAVIORAL HEALTH

Measure/coding tips	Measure description	Documentation required	Coding
Antidepressant Medication Management (AMM)	Members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported: <b>1. Effective acute</b> <b>phase treatment:</b> The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks). <b>2. Effective continuation</b> <b>phase. treatment:</b> The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks).	<ul> <li>The Intake Period (IP) is the 12-month window starting on May1 of the year prior to the MY and ending on April 30 of the MY.</li> <li>The IPSD is the earliest dispensing date for an antidepressant medication in the IP.</li> <li><b>Required exclusions:</b> Members who meet any of the following criteria are excluded from the measure: <ul> <li>In hospice or using hospice services any time in the MY.</li> </ul> </li> <li>No encounter with diagnosis of major depression during the 121-day period from 60 days prior to the IPSD, through 60 days after the IPSD. </li> <li><b>Optional exclusions:</b> Noncompliant members may be excluded from the measure with documentation of any of the following: <ul> <li>Deceased in the MY.</li> </ul> </li> </ul>	Members are identified through administrative claims and pharmacy claims. Major depression diagnosis: ICD-10-CM: F32.0, F32.1, F32.2, F32.3, F32.4, F32.9, F33.0, F33.1, F33.2, F33.3, F33.41, F33.9 Antidepressant medications: Miscellaneous antidepressants: bupropion, vilazodone, vortioxetine Monoamine oxidase inhibitors (MAOIs): iscorboxazid, phenelzine, selegiline, Tranylcypromine Phenylpiperazine antidepressants: nefazodone, trazodone Psychotherapeutic combinations: amitriptyline- chlordiazepoxide, amitriptyline-perphenazine, fluoxetine-olanzapine Serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants: desvenlafaxine, duloxetine, levomilnacipran, venlafaxine Selective serotonin reuptake inhibitor (SSRI) antidepressants: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline Tetracyclic antidepressants: amitriptyline, amoxapine, clomipramine, desipramine, doxepin (>6 mg), imipramine, nortriptyline, protriptyline, trimipramine Note: LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information.



### Follow-Up Care for Children Prescribed ADHD Medication (ADD)

This is also a measure (ADD-E) collected through Electronic Clinical Data Systems. Please discuss options for a direct data feed with your Account Executive. Direct data feeds can improve provider quality performance and reduce the burden of medical record requests. The percentage of children 6 – 12 years of age who had a newly prescribed ADHD medication and who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed.

Two rates are reported:

#### 1. Initiation phase:

Members who had one follow-up visit with practitioner with prescribing authority during the 30 days following the IPSD.

#### 2. Continuation phase:

Members who remained on the medication for at least 210 days, had a visit in the initiation phase, and had at least two follow-up visits within 270 days after the initiation phase ended. The Intake Period (IP) is the 12-month window starting March 1 of the year prior to the measurement year (MY) and ending the last calendar day of February of the MY.

The IPSD is the earliest prescription dispensing date for an ADHD medication in the IP.

Telephone and telehealth visits are acceptable in both the initiation and continuation phases.

Only one of the two continuation phase visits can be e-visit or virtual check.

#### **Required exclusions:**

Members who meet any of the following criteria are excluded from the measure:

- In hospice or using hospice services any time in the MY.
- Acute inpatient encounter or discharge with principal diagnosis of mental, behavioral, or neurodevelopmental disorder.

#### **Optional exclusions:**

Noncompliant members may be excluded from the measure with documentation of any of the following:

- Diagnosis of narcolepsy.
- Deceased in the MY.

# Members are identified through administrative claims and pharmacy claims.

#### ADHD medications:

CNS stimulants: dexmethylphenidate, dextroamphetamine, lisdexamfetamine, methylphenidate, methamphetamine. Alpha-2 receptor agonists: clonidine, guanfacine Miscellaneous ADHD medications: atomoxetine

Visit setting unspecified (with outpatient POS, partial hospitalization POS, Community Mental Health Center POS, or Telehealth POS):

**CPT:** 90791, 90792, 90832, 90833, 90834, 90836, 90837, 90838, 90839, 90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221, 99222, 99223, 99231, 99232, 99233, 99238, 99239, 99251, 99252, 99253, 99254, 99255

#### **Outpatient POS:**

**POS:** 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 71, 72

Partial hospitalization POS:

POS: 52

Community mental health center POS: POS: 53

Telehealth POS: POS: 02

#### Behavioral health (BH) outpatient:

**CPT:** 98960, 98961, 98962, 99078, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99245, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99381, 99382, 99383, 99384, 99385, 99386, 99387, 99391, 99392, 99393, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99483, 99510

HCPCS: G0155, G0176, G0177, G0409, G0463, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013, H2014, H2015, H2016, H2017, H2018, H2019, H2020, T1015

**UBREV:** 0510, 0513, 0515, 0516, 0517, 0519, 0520, 0521, 0522, 0523, 0526, 0527, 0528, 0529, 0900, 0902, 0903, 0904, 0911, 0914, 0915, 0916, 0917, 0919, 0982, 0983

**Observation: CPT:** 99217, 99218, 99219, 99220

Health and behavior assessment or intervention: CPT: 96150, 96151, 96152, 96153, 96154, 96156, 96158, 96159, 96164, 96165, 96167, 96168, 96170, 96171

Partial hospitalization or intensive outpatient: HCPCS: G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485

**UBREV:** 0905, 0907, 0912, 0913

Telephone visit:

**CPT:** 98966, 98967, 98968, 99441, 99442, 99443

Online assessments: (continuation phase,one of two visits): CPT: 98969, 98970, 98971, 98972, 98972, 99421, 99422, 99423, 99444, 99457, 99458

HCPCS: G0071, G2010, G2012, G2061, G2062, G2063 Note: LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information.



#### **EFFECTIVENESS OF CARE: BEHAVIORAL HEALTH** Measure/coding tips Measure description **Documentation required** Coding **Follow-Up After** Percentage of discharges The measurement year (MY) is January 1 -Mental illness diagnosis: ICD-10: F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F21, F22, F23, F24, F25.0, F25.1, F25.8, F25.9, F28, for members 6 years December 31. **Hospitalization for** of age and older who An outpatient visit with a mental health provider F29, F30.10, F30.11, F30.12, F30.13, F30.2, F30.3, F30.4, Mental Illness (FUH) were hospitalized for F30.8, F30.9, F31.0, F31.10, F31.11, F31.12, F31.13, F31.2 within seven and 30 days after discharge. Do not treatment of selected F31.30, F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, include visits that occur on the date of discharge. mental illness or F31.63, F31.64, F31.70, F31.71, F31.72, F31.73, F31.74, A visit with a mental health provider in any of the F31.75, F31.76, F31.77, F31.78, F31.81, F31.89, F31.9, F32.0, intentional self-harm following settings: F32.1, F32.2, F32.3, F32.4, F32.5, F32.8, F32.81, F32.89, diagnoses and who had F32.9, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42 · Outpatient. a follow-up visit with a F33.8, F33.9, F34.0, F34.1, F34.8, F34.81, F34.89, F34.9, F39, mental health provider. F42, F42.2, F42.3, F42.4, F42.8, F42.9, F43.0, F43.10, F43.11, Behavioral health outpatient. F43.12, F43.20, F43.21, F43.22, F43.23, F43.24, F43.25 F43.29, F43.8, F43.9, F44.89, F53, F53.0, F53.1, F60.0, F60.1 Two rates are reported: Telehealth visit. F60.2, F60.3, F60.4, F60.5, F60.6, F60.7, F60.81, F60.89, F60.9, F63.0, F63.1, F63.2, F63.3, F63.81, F63.89, F63.9, F68.10. 1. The percentage of Telephone visit. F68.11, F68.12, F68.13, F68.8, F68.A, F84.0, F84.2, F84.3, discharges for which Observation visit. F84.5, F84.8, F84.9, F90.0, F90.1, F90.2, F90.8, F90.9, F91.0, the member received F91.1, F91.2, F91.3, F91.8, F91.9, F93.0, F93.8, F93.9, F94.0, • Transitional care management visit. follow-up within 30 F94.1, F94.2, F94.8, F94.9 days of discharge. · A visit in any of the following settings: Intentional self-harm diagnosis: · Intensive outpatient/partial hospitalization. **ICD-10-CM:** T14.91XA, T14.91XD, T14.91XS, T36.0X2A, T36.0X2D, T36.0X2S, T36.1X2A, T36.1X2D, T36.1X2D, T36.1X2S, 2. The percentage of discharges for which · Community mental health center. T36.2X2A, T36.2X2D, T36.2X2S, T36.3X2A, T36.3X2D, the member received T36.3X2S, T36.4X2A, T36.4X2D, T36.4X2S, T36.5X2A, Electroconvulsive therapy visit. follow-up within seven T36.5X2D, T36.5X2S, T36.6X2A, T36.6X2D, T36.6X2S, days of discharge. Behavioral health care setting. T36.7X2A, T36.7X2D, T36.7X2S, T36.8X2A, T36.8X2D, T36.8X2S, T36.92XA, T36.92XD, T36.92XS, T37.0X2A, Common chart deficiencies: T37.0X2D, T37.0X2S, T37.1X2A, T37.1X2D, T37.1X2S, Follow-up visit less than seven days or more T37.2X2A, T37.2X2D, T37.2X2S, T37.3X2A, T37.3X2D, than 30 days after discharge. T37.3X2S, T37.4X2A, T37.4X2D, T37.4X2S, T37.5X2A, T37.5X2D, T37.5X2S, T37.8X2A, T37.8X2D, T37.8X2S, **Required exclusions:** T37.92XA, T37.92XD, T37.92XS, T38.0X2A, T38.0X2D, Members who meet any of the following T38.0X2S, T38.1X2A, T38.1X2D, T38.1X2S, T38.2X2A, T38.2X2D, T38.2X2S, T38.3X2A, T38.3X2D, T38.3X2S, T38.4X2A, T38.4X2D, T38.4X2D, T38.4X2D, T38.4X2D, T38.4X2D, T38.5X2D, T38.5X criteria are excluded from the measure: · In hospice or using hospice services any T38.5X2S, T38.6X2A, T38.6X2D, T38.6X2S, T38.7X2A, time in the MY. T38.7X2D, T38.7X2S, T38.802A, T38.802D, T38.802S, T38.812A, T38.812D, T38.812S, T38.892A, T38.892D, **Optional exclusions:** T38.892S, T38.902A, T38.902D, T38.902S, T38.992A, Noncompliant members may be excluded T38.992D, T38.992S, T39.012A, T39.012D, T39.012S, from the measure with documentation of T39.092A, T39.092D, T39.092S, T39.1X2A, T39.1X2D, any of the following: T39.1X2S, T39.2X2A, T39.2X2D, T39.2X2S, T39.312A, · Deceased in the MY. T39.312D, T39.312S, T39.392A, T39.392D, T39.392S, T39.4X2A, T39.4X2D, T39.4X2S, T39.8X2A, T39.8X2D, T39.8X2S, T39.92XA, T39.92XD, T39.92XS, T40.0X2A, T40.0X2D, T40.0X2S, T40.1X2A, T40.1X2D, T40.1X2S, T40.2X2A, T40.2X2D, T40.2X2S, T40.3X2A, T40.3X2D, T40.3X2S, T40.412A, T40.412D, T40.412S, T40.422A, 40.422b, T40.422S, T40.422A, T40.412S, T40.422b, T40.422b, T40.422b, T40.422b, T40.492A, T40.492b, T40.492S, T40.4X2b, T40.5X2b, T40.5X2b, T40.5X2b, T40.602A, T40.602D, T40.602S, T40.602S, T40.692A, T40.692D, T40.692D, T40.692S, T40.7X2b, T40.7X2 T40.8X2A, T40.8X2D, T40.8X2S, T40.902A, T40.902D, T40.902S, T40.992A, T40.992D, T40.992S, T41.0X2A, T41.0X2D, T41.0X2S, T41.1X2A, T41.1X2D, T41.1X2S, T41.202A, T41.202D, T41.202S, T41.292A, T41.292D, T41.292S, T41.3X2A, T41.3X2D, T41.3X2S, T41.42XA, T41.42XD, T41.42XS, T41.5X2A, T41.5X2D, T41.5X2S, T42.0X2A, T42.0X2D, T42.0X2S, T42.1X2A, T42.1X2D, T42.1X2S, T42.2X2A, T42.2X2D, T42.2X2S, T42.3X2A, T42.3X2D, T42.3X2S, T42.4X2A, T42.4X2D, T42.4X2S, T42.5X2A, T42.5X2D, T42.5X2S, T42.6X2A, T42.6X2D, T42.6X2S, T42.72XA, T42.72XD, T42.72XS, T42.8X2A, T42.8X2D, T42.8X2S, T43.012A, T43.012D, T43.012S, T43.022A, T43.022D, T43.022S, T43.1X2A, T43.1X2D, T43.1X2S, T43.202A, T43.202D, T43.202S, T43.212A, T43.212D, T43.212S, T43.202D, T43.222D, T43.222S, T43.292A, T43.292D, T43.292S, T43.3X2A, T43.3X2D, T43.3X2S, T43.4X2A, T43.4X2D, T43.4X2S, T43.502A, T43.502D, T43.502S, T43.592A, T43.592D, T43.592S, T43.602A, T43.602D, T43.602S, T43.612A, T43.612D, T43.612S, T43.622A, T43.622D, T43.622S, T43.632A, T43.632D, T43.632S, T43.642A, T43.642D, T43.642S, T43.692A, T43.692D, T43.692S, T43.8X2A, T43.8X2D, T43.8X2S, T43.92XA, T43.92XD, T43.92XS, T44.0X2A, T44.0X2D, T44.0X2S, T44.1X2A, T44.1X2D, T44.1X2S, T44.2X2A, T44.2X2D, T44.2X2S, T44.3X2A, T44.3X2D, T44.3X2S, T44.4X2A, T44.4X2D, T44.4X2S, T44.5X2A, T44.5X2D, T44.5X2D, T44.5X2D, T44.6X2D, T44.6X2D, T44.6X2D, T44.5X2D, T44.5X2D, T44.5X2D, T44.7X2D, T44.7X2D, T44.8X2D, T44.8X2D, T44.8X2D, T44.902D, T44.902D, T44.902D, T44.902D, T44.902D, T44.902D, T44.902D, T45.0X2D, T45.0X2D, T45.0X2S, T45.0X

T45.1X2A, T45.1X2D, T45.1X2S, T45.2X2A, T45.2X2D,



Measure/coding tips	Coding
Measure/coding tips Follow-Up After Hospitalization for Mental Illness (FUH) (Continued from page 3)	145.2X25, T45.3X26, T45.3X26, T45.4X26, T45.4X20, T45.4X25, T45.5127, T45.5122, T45.5122, T45.5227, T55.527, T
	Transitional care management services (with community mental health center POS with mental health provider): CPT: 99495, 99496 Electroconvulsive therapy (with ambulatory surgical center POS, community mental health center POS, outpatient POS, or partial

POS: 52 Telehealth POS:

POS: 2

Note: LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information.



EFFECTIVENESS	EFFECTIVENESS OF CARE: BEHAVIORAL HEALTH		
Measure/coding tips	Measure description	Documentation required	Coding
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who are Using Antipsychotic Medications (SSD)	The percentage of members ages 18 – 64 with schizophrenia, schizoaffective disorder, or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year (MY).	<ul> <li>A glucose test or HbA1c test performed during the MY.</li> <li><b>Required exclusions:</b> Members who meet any of the following criteria are excluded from the measure: <ul> <li>In hospice or using hospice services any time in the MY.</li> <li>Diabetes.</li> </ul> Optional exclusions: Noncompliant members may be excluded from the measure with documentation of any of the following: <ul> <li>Deceased in the MY.</li> </ul></li></ul>	Glucose lab test: CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 HbA1c lab test: CPT: 83036, 83037 HbA1c test result or finding: CPT-CAT-II: 3044F, 3046F, 3051F, 3052F Antipsychotic medications: Miscellaneous antipsychotic agents: aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, haloperidol, iloperidone, loxapine, lurasidone, molindone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone Phenothiazine antipsychotics: chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine Psychotherapeutic combinations: amitriptyline-perphenazine Thioxanthenes: thiothixene Long-acting injections: aripiprazole, fluphenazine decanoate, haloperidol decanoate, olanzapine, paliperidone palmitate, risperidone Note: LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information.
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	The percentage of members 18 – 64 years of age with schizophrenia or schizoaffective disorder and diabetes who had both a low-density lipoprotein cholesterol (LDL-C) test and an HbA1c test during the Measurement Year (MY).	<ul> <li>An HbA1c test and an LDL-C test performed in the MY.</li> <li>Required exclusions: Members who meet any of the following criteria are excluded from the measure: <ul> <li>In hospice or using hospice services any time in the MY.</li> </ul> </li> <li>Optional exclusions: Noncompliant members may be excluded from the measure with documentation of any of the following: <ul> <li>Do not have a diagnosis of diabetes during the MY and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes, or steroid-induced diabetes in the MY or the year prior.</li> <li>Deceased in the MY.</li> </ul> </li> </ul>	HbA1c lab test: CPT: 83036, 83037 HbA1c test result or finding: CPT-CAT-II: 3044F, 3046F, 3051F, 3052F LDL-C lab test: CPT: 80061, 83700, 83701, 83704, 83721 LDL-C test result or finding: CPT-CAT-II: 3048F, 3049F, 3050F Must have both A1c and LDL. Note: LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC)	The percentage of members 18 – 64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease (IVD, CABG, PCI, AMI) who had an LDL-C test during the measurement year (MY).	<ul> <li>An LDL-C test performed during the MY.</li> <li><b>Required exclusions:</b></li> <li>Members who meet any of the following criteria are excluded from the measure:</li> <li>In hospice or using hospice services any time in the MY.</li> <li><b>Optional exclusions:</b></li> <li>Noncompliant members may be excluded from the measure with documentation of any of the following:</li> <li>Deceased in the MY.</li> </ul>	LDL-C lab test: CPT: 80061, 83700, 83701, 83704, 83721 LDL-C test result or finding: CPT-CAT-II: 3048F, 3049F, 3050F Note: LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information.



Measure/coding tips	Measure description	Documentation required	Coding
Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)	The percentage of members 18 years of age and older during the MY with schizophrenia or schizoaffective disorder who were dispensed and remained on an oral or long-acting injection antipsychotic medication at least 80% of their treatment period.	<ul> <li>The index prescription start date (ISPD) is the earliest prescription dispensing date during the MY.</li> <li>The treatment period is the ISPD through the last day of the MY.</li> <li><b>Required exclusions:</b> Members who meet any of the following criteria are excluded from the measure: <ul> <li>In hospice or using hospice services any time in the MY.</li> <li>66 – 80 years of age with frailty <b>and</b> advanced illness during the MY.</li> <li>81 years of age and older with frailty.</li> <li>Diagnosis of dementia in the MY.</li> </ul> <b>Optional exclusions:</b> Noncompliant members may be excluded from the measure with documentation of any of the following: <ul> <li>Deceased in the MY.</li> </ul> </li> </ul>	Long-acting injections, 14-day supply: HCPCS: J2794 Long-acting injections, 28-day supply: HCPCS: C9035, J0401, J1631, J1943, J1944, J2358, J2426, J2680 Long-acting injections, 30-day supply: HCPCS: C9037, J2798 Oral antipsychotic medications: Miscellaneous antipsychotic agents: aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, haloperidol, iloperidone, loxapine, lurasidone, molindone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone Phenothiazine antipsychotics: chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine Psychotherapeutic combinations: amitriptyline-perphenazine Thioxanthenes: thiothixene Long-acting injections: 14-day supply: risperidone (excluding Perseris®) long-acting injections, 14-day supply 28-day supply: risperidone (Perseris®) Schizophrenia diagnosis: ICD-10-CM: F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F25.0, F25.1, F25.8, F25.9 Note: LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information.
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)	Adolescent and adult members with a <b>new</b> episode of alcohol or other drug abuse (AOD) dependence who received initiation of AOD treatment or engagement of AOD treatment. Two rates are reported: 1. Initiation of AOD treatment: Members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth or medication treatment within 14 days of the diagnosis. 2. Engagement of AOD treatment: The percentage of members who initiated treatment and who had two or more additional AOD services or medication treatment within 34 days of the initiation visit.	<ul> <li>The measurement year (MY) is January 1 – December 31.</li> <li>Note: <ul> <li>Methadone is not included in the medication lists for the measure.</li> <li>Medication treatment meets criteria for members being treated for alcohol or opioid abuse or dependence. It does not meet the criteria for treatment of other drug abuse or dependence.</li> </ul> </li> <li>Required exclusions: <ul> <li>Members who meet any of the following criteria are excluded from the measure:</li> <li>In hospice or using hospice services any time in the MY.</li> </ul> </li> <li>Optional exclusions: <ul> <li>Noncompliant members may be excluded from the measure with documentation of any of the following:</li> <li>Deceased in the MY.</li> </ul> </li> </ul>	Opioid use disorder (OUD) monthly office-based treatment (if service that bills monthly or diagnosis from opioid abuse or dependence): HCPCS: G2086, G2087 IET stand-alone visits (with alcohol abuse and dependence, opioid abuse or dependence or other drug abuse or dependence): CPT: 98960, 98961, 98962, 99078, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99408, 99409, 99411, 99412, 99483, 99510 HCPCS: G0155, G0176, G0177, G0396, G0397, G0409, G0411 G0411, G0443, G0463, H0001, H0002, H0004, H0005, H0007 H0015, H0016, H0022, H0031, H0034, H0035, H0036, H0037 H0039, H0040, H0047, H2001, H2011, H2012 H2013, H2014, H2015, H2016, H2017, H2018, H2019, H2020 H2035, H2036, S0201, S9480, S9484, S9485, T1006, T1012, T1015 UBREV: 0510, 0513, 0515, 0516, 0517, 0519, 0520, 0521, 0522, 0523, 0526, 0527, 0528, 0529, 0900, 0902, 0903, 0904 0905, 0906, 0907, 0911, 0912, 0913, 0914, 0915, 0916, 0917 0919, 0944, 0945, 0982, 0983 Observation (with alcohol abuse or dependence, opioid abuse or dependence, or other drug abuse or dependence): CPT: 99217, 99218, 99219, 99220 Telephone visit (with alcohol abuse or dependence, opioid abuse or dependence, or other drug abuse or dependence): CPT: 98966, 98967, 98968, 99441, 99442, 99443 Alcohol abuse or dependence: ICD-10-CM: F10.10, F10.120, F10.121, F10.129, F10.130, F10.131, F10.132, F10.139, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, F10.188, F10.19, F10.220, F10.220, F10.221, F10.229, F10.230, F10.231, F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280, F10.281, F10.282, F10.288, F10.29



Measure/coding tips	Coding		
Measure/coding tips Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET) (Continued from page 6)	Opioid abuse or depende ICD-10-CM: F11.10, F11.1 F11.20, F11.220, F11.221 Other drug abuse or dep ICD-10-CM: F12.10, F12.2 F13.131, F13.132, F13.13 F13.229, F13.230, F13.22 F13.29, F14.10, F14.120, F14.29, F14.20, F14.220, F14.29, F15.10, F14.220, F15.29, F16.10, F14.120, F15.29, F16.10, F14.120, F16.220, F16.221, F16.22 F18.14, F18.150, F18.151 F18.259, F18.27, F18.280 F19.150, F19.151, F19.12 F19.230, F19.231, F19.23 IET visits group 1 (with II dependence): CPT: 90791, 90792, 9083 IET POS group 1: POS: 02, 03, 05, 07, 09, 11 IET visits group 2 (with II dependence): CPT: 99221, 99222, 99222 IET POS group 2: POS: 02, 52, 53 Online assessments (witt CPT: 98969, 98970, 9897 HCPCS: G2071, G2010, G OUD weekly nondrug ser HCPCS: G2067, G2068, G AOD medication treatme HCPCS: H0020, H0033, J0 Alcohol use disorder treat Aldehyde dehydrogenase Antagonist: naltrexone (o	120, F11.121, F11.122, F11.129, F11.13, F11.14, F1 I, F11.222, F11.229, F11.23, F11.24, F11.250, F11.22 endence: 120, F12.121, F12.122, F12.129, F12.13, F12.150, F 129, F12.23, F12.250, F12.251, F12.259, F12.280, F13 30, F13.232, F13.239, F13.24, F13.150, F13.180, F13 31, F13.232, F13.239, F13.24, F13.250, F13.251, F13 F14.121, F14.122, F14.129, F14.13, F14.14, F14.155 F14.121, F14.122, F14.129, F14.13, F14.14, F14.155 F15.221, F15.222, F15.229, F15.23, F15.24, F15.255 F16.121, F16.122, F16.129, F16.14, F16.150, F16.1 129, F16.24, F16.250, F16.251, F16.259, F16.280, F16 I, F18.159, F18.17, F18.180, F18.188, F18.19, F18.2 D, F18.288, F18.29, F19.10, F19.120, F19.121, F19.1 39, F19.16, F19.17, F19.180, F19.181, F19.182, F19. 32, F19.239, F19.24, F19.250, F19.251, F19.259, F16 ET POS group 1 and alcohol abuse or dependence, of 32, 90833, 90834, 90836, 90837, 90838, 90839, 908 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 52 ET POS group 2 and alcohol abuse or dependence, of 32, 99231, 99232, 99233, 99238, 99239, 99251, 992 h alcohol abuse or dependence, opioid abuse or dependence 2075, G2076, G2077, G2080 ent service (if diagnosis from opioid abuse or dependence 2075, G2076, G2077, G2080 ent service (if diagnosis from opioid abuse or dependence 2069, G2070, G2072, G2073 ent (if diagnosis from alcohol abuse or dependence 0570, J0571, J0572, J0573, J0574, J0575, J2315, O ent service (if diagnosis from opioid abuse or dependence 0570, J0571, J0572, J0573, J0574, J0575, J2315, O ent medications list (if diagnosis from alcohol abuse or dependence 0570, J0571, J0572, J0573, J0574, J0575, J2315, O ent medications list (if diagnosis from opioid abuse or dependence 0570, J0571, J0572, J0573, J0574, J0575, J2315, O entipitor: disulfiram (oral) ral and injectable) delayed-release tablet) tement medications (if diagnosis from opioid abuse or dependence 0570, J0571, J0572, J0573, J0574, J0575, J2315, O entipitor: disulfiram (oral) ral and injectable) relayed-release tablet)	12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220, 2.288, F12.29, F13.10, F13.120, F13.121, F13.129, F13.130, 3.181, F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, 3.259, F13.26, F13.27, F13.280, F13.281, F13.282, F13.288, 0, F14.151, F14.159, F14.180, F14.181, F14.182, F14.188, 0, F14.51, F14.559, F14.280, F14.281, F14.282, F14.288, 0, F15.151, F15.159, F15.180, F15.181, F15.182, F15.188, 0, F15.251, F15.259, F15.280, F15.281, F15.282, F15.288, 51, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, 6.283, F16.288, F16.29, F18.10, F18.120, F18.121, F18.129, 0, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, 22, F19.129, F19.130, F19.131, F19.132, F19.139, F19.14, 188, F19.19, F19.20, F19.220, F19.221, F19.222, F19.229, 9.26, F19.27, F19.280, F19.281, F19.282, F19.288, F19.29 0pioid abuse or dependence or other drug abuse or 840, 90845, 90847, 90849, 90853, 90875, 90876 252, 99253, 99254, 99255 pendence or other drug abuse or dependence): 457, 99458 e): modence): or opioid abuse or dependence): appendence or other drug abuse or dependence): appendence): modenc
		phine (sublingual tablet, injection, implant), buprenor D codes can be captured through electronic data sub	phine/naloxone (sublingual tablet, buccal film, sublingual film) missions. Please contact your Account Executive for
Measure/coding tips	Measure description	Documentation required	Coding
Measure/coung tips Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Children and adolescents ages 1 –17 who had two or more antipsychotic prescriptions and had metabolic testing.	<ul> <li>Both of the following during the MY.</li> <li>At least one test for blood glucose or HbA1c.</li> <li>At least one test for low-density lipoprotein cholesterol (LDL-C) or cholesterol.</li> <li>Required exclusions: Members who meet any of the following criteria are excluded from the measure:</li> <li>In hospice or using hospice services any time in the MY.</li> <li>Optional exclusions: Noncompliant members may be excluded from the measure with documentation of any of the following:</li> <li>Deceased in the MY.</li> </ul>	CountgMembers are identified through administrative claims and pharmacy claims.Glucose lab test: CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951HbA1c lab test: CPT: 83036, 83037HbA1c test result or finding: CPT-CAT-II: 3044F, 3046F, 3051F, 3052FCholesterol lab test: CPT: 82465, 83718, 83722, 84478LDL-C lab test: CPT: 80061, 83700, 83701, 83704, 83721LDL-C test result or finding: CPT-CAT-II: 3048F, 3049F, 3050FNote: LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information.



#### **EFFECTIVENESS OF CARE: BEHAVIORAL HEALTH** Measure/coding tips Measure description **Documentation required** Coding **Follow-Up After** The percentage of A follow up visit with any practitioner, with a principal Mental illness diagnosis: ICD-10: F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F21, F22, F23, F24, F25.0, F25.1, F25.8, F25.9, F28, F29, emergency department diagnosis of a mental health disorder or with a Emergency principal diagnosis of intentional self-harm and (ED) visits for members F30.10, F30.11, F30.12, F30.13, F30.2, F30.3, F30.4, F30.8, **Department Visit** any diagnosis of a mental health disorder within 6 years of age and older F30.9, F31.0, F31.10, F31.11, F31.12, F31.13, F31.2, F31.30, for Mental Illness 7 and 30 days after ED visit. Include outpatient with a principal diagnosis F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, F31.63, visits, behavioral health outpatient visits, intensive (FUM) of mental illness or F31.64, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, outpatient visits, partial hospitalizations, community F31.76, F31.77, F31.78, F31.81, F31.89, F31.9, F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.8, F32.81, F32.89, F32.9, F33.0, intentional self-harm. mental health visits, electroconvulsive therapy visits, who had a follow-up visit F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.8, F33.9, telehealth visits, and observation visits. for mental illness. F34.0, F34.1, F34.8, F34.81, F34.89, F34.9, F39, F42, F42.2, Includes visits that occur on the date of the FD visit F42.3, F42.4, F42.8, F42.9, F43.0, F43.10, F43.11, F43.12, Two rates are reported: F43.20, F43.21, F43.22, F43.23, F43.24, F43.25, F43.29, F43.8, Telephone visits, e-visits and virtual check-ins are F43.9, F44.89, F53, F53.0, F53.1, F60.0, F60.1, F60.2, F60.3, F60.4, F60.5, F60.6, F60.7, F60.81, F60.89, F60.9, F63.0, F63.1, 1. The percentage of acceptable. ED visits for which F63.2, F63.3, F63.81, F63.89, F63.9, F68.10, F68.11, F68.12 Required exclusions: F68.13, F68.8, F68.A, F84.0, F84.2, F84.3, F84.5, F84.8, F84.9, the member received Members who meet any of the following criteria F90.0, F90.1, F90.2, F90.8, F90.9, F91.0, F91.1, F91.2, F91.3, follow-up within 30 are excluded from the measure: F91.8, F91.9, F93.0, F93.8, F93.9, F94.0, F94.1, F94.2, F94.8, days of the ED visit F94.9 · In hospice or using hospice services (31 total days). any time in the MY. Intentional self-harm diagnosis: ICD-10-CM: T14.91XA, T14.91XD, T14.91XS, T36.0X2A, T36.0X2D, T36.0X2S, T36.1X2A, T36.1X2D, T36.1X2S, 2. The percentage of **Optional exclusions:** ED visits for which Noncompliant members may be excluded T36.2X2A, T36.2X2D, T36.2X2S, T36.3X2A, T36.3X2D, the member received from the measure with documentation of T36.3X2S, T36.4X2A, T36.4X2D, T36.4X2S, T36.5X2A, follow-up within T36.5X2D, T36.5X2S, T36.6X2A, T36.6X2D, T36.6X2S, T36.7X2A, T36.7X2D, T36.7X2S, T36.8X2A, T36.8X2D, any of the following: 7 days of the ED visit Deceased in the MY. T36.8X2S, T36.92XA, T36.92XD, T36.92XS, T37.0X2A, T37.0X2D, T37.0X2S, T37.1X2A, T37.1X2D, T37.1X2S, (8 total days). T37.2X2A, T37.2X2D, T37.2X2S, T37.3X2A, T37.3X2D, T37.3X2S, T37.4X2A, T37.4X2D, T37.4X2S, T37.5X2A, T37.5X2D, T37.5X2S, T37.4A2A, T37.4A2D, T37.4A2D, T37.5X2D, T37.5X2S, T37.5X2S, T37.8X2A, T37.8X2D, T37.8X2D, T37.92XA, T37.92XA, T37.92XS, T38.0X2A, T38.0X2D, T38.0X2S, T38.1X2A, T38.1X2D, T38.1X2S, T38.2X2A, T38.2X2D, T38.2X2S, T38.3X2A, T38.3X2A, T38.3X2D, T38.3X2S, T38.4X2A, T38.4X2D, T38.4X2S, T38.5X2A, T38.5X2D, T38.5X2S, T38.6X2A, T38.6X2D, T38.6X2S, T38.7X2A, T38.7X2D, T38.7X2S, T38.802A, T38.802D, T38.802S, T38.812A, T38.812D, T38.02A, T38.892A, T38.892D, T38.892S, T38.902A, T38.902D, T38.902S, T38.992A, T38.992D, T38.992S, T39.012A, T39.012D, T39.012S, T39.092A, T39.092D, T39.092S, T39.1X2A, T39.1X2D, T39.092A, T39.092D, T39.092S, T39.1X2A, T39.1X2D, T39.1X2S, T39.2X2A, T39.2X2D, T39.2X2S, T39.312A, T39.3120, T39.3125, T39.392A, T39.392D, T39.392S, T39.4X2A, T39.4X2D, T39.4X2S, T39.8X2A, T39.8X2D, T39.8X2S, T39.92XA, T39.92XD, T39.92XS, T40.0X2A, T40.0X2D, T40.0X2S, T40.1X2A, T40.1X2D, T40.1X2S, T40.2X2A, T40.2X2D, T40.2X2S, T40.3X2A, T40.3X2D, T40.3X2S, T40.412A, T40.412D, T40.412S, T40.422A, T40.422D, T40.422S, T40.492A, T40.492D, T40.492S, T40.4X2A, T40.4X2D, T40.4X2S, T40.5X2A, T40.5X2D, T40.5X25, T40.602A, T40.602D, T40.602S, T40.602A, T40.692D, T40.692D, T40.692S, T40.7X2A, T40.7X2D, T40.7X2S, T40.8X2A, T40.8X2D, T40.8X2S, T40.902A, T40.902D, T40.902S, T40.992A, T40.992D, T40.992S, T41.0X2A, T41.0X2D, T41.0X2D, T41.0X2S, T41.1X2A, T41.1X2D, T41.1X2S, T41.202A, T41.202D, T41.202S, T41.292A, T41.292D, T41.2925, T41.3X2A, T41.3X2D, T41.3X25, T41.42XA, T41.42XD, T41.42XS, T41.5X2A, T41.5X2D, T41.42XA, T42.0X2A, T42.0X2D, T42.0X2S, T42.1X2A, T42.1X2D, T42.1X2S, T42.2X2A, T42.2X2D, T42.2X2S, T42.3X2A, T42.3X2D, T42.3X2D, T42.3X2S, T42.4X2A, T42.4X2D, T42.4X2S, T42.5X22, T42.5X2D, T42.5X2S, T42.6X2A, T42.6X2D, T42.6X2S, T42.72XA, T42.72XD, T42.72XS, T42.6X2A, T42.6X2S, T42.72XA, T42.72XD, T42.72XS, T42.8X2A, T42.8X2D, T42.8X2S, T43.012A, T43.012D, T43.012S, T43.022A, T43.022D, T43.022S, T43.1X2A, T43.1X2D, T43.1X2S, T43.202A, T43.202D, T43.202S, T43.212A, T43.1X2S, T43.202A, T43.202D, T43.202S, T43.212A, T43.212D, T43.202A, T43.202A, T43.202A, T43.222A, T43.222A, T43.222A, T43.222A, T43.222A, T43.292A, T43.292A, T43.302A, T43.302A, T43.302B, T43.502D, T43.502A, T43.502A, T43.502D, T43.602A, T43 T43.612S, T43.622A, T43.622D, T43.622S, T43.632A, T43.632D, T43.6322, T43.642A, T43.642D, T43.642Z, T43.632D, T43.632S, T43.642A, T43.642D, T43.642Z, T43.692A, T43.692D, T43.692S, T43.8X2A, T43.8X2D, T43.8X2S, T43.92XA, T43.92XD, T43.92XS, T44.0X2A, T44.0X2D, T44.0X2S, T44.1X2A, T44.1X2A, T44.1X2D, T44.1X2S, T44.2X2A, T44.2X2D, T44.2X2D, T44.2X2S, T44.3X2D, T44.3X2D, T44.2X2A, T44.2X2A, T44.2X2D, T44.2X2S, T44.3X2D, T44.3X2D, T44.2X2A, T44.2X2A, T44.3X2D, T44.3X2D, T44.2X2A, T44.2X2A, T44.2X2A, T44.2X2A, T44.2X2A, T44.3X2D, T44.3X2D, T44.2X2A, T44.3X2D, T44.3X2D, T44.2X2A, T44.2X T44.3X2S, T44.4X2A, T44.4X2D, T44.4X2S, T44.5X2A, T44.5X2D, T44.5X2S, T44.6X2A, T44.6X2D, T44.6X2S, T44.7X2A, T44.7X2D, T44.7X2S, T44.8X2A, T44.8X2D, T44.8X2S, T44.902A, T44.902D, T44.902S, T44.992A, T44.992D, T44.9925, T45.0X2A, T45.0X2D, T45.0X2S, T45.1X2A, T45.1X2D, T45.1X2S, T45.2X2A, T45.2X2D, T45.2X2S, T45.3X2A, T45.3X2D, T45.3X2S, T45.4X2A,

T45.4X2D, T45.4X2S, T45.512A, T45.512D, T45.512S,



Measure/coding tips	Coding
Measure/coding tips Follow-Up After Emergency Department Visit for Mental Illness (FUM) (Continued from page 8)	1455220, T455220, T455225, T456020, T456025, T456120, T456125, T456220, T456225, T456220, T456225, T456920, T456225, T456920, T456225, T456220, T456225, T46920,
	health): CPT: 90791, 90792, 90832, 90833, 90834, 90836, 90837, 90838, 90839, 90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221, 99222, 99223, 99231, 99232, 99233, 99238, 99239, 99251, 99252, 99253, 99254, 99255 BH outpatient (with principal diagnosis of mental health or principal diagnosis of intentional self-harm with any diagnosis of mental health): CPT: 98960, 98961, 98962, 99078, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99381, 99382, 99383, 99384, 99385, 99386, 99387, 99391, 99392, 99393, 99395, 99395, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99483, 99510 HPCS: 60155, 60176, 60177, 60409, 60463, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013, H2014, H2015, H2016, H2017, H2019, H2020, T1015 UBREV: 0510, 0513, 0516, 0517, 0519, 0520, 0521, 0522, 0523, 0526, 0527, 0528, 0529, 0900, 0902, 0903, 0904, 0911, 0914, 0915, 0916, 0917, 0919, 0982, 0983 Partial hospitalization or intensive outpatient (with principal diagnosis of mental health or principal diagnosis of intentional self-harm with any diagnosis of mental health): HCPCS: G0410, H0035, H2001, H2012, S0201, S9480, S9484, S9485 UBREV: 0905, 0907, 0912, 0913 Electroconvulsive therapy (with ambulatory surgical center POS, community mental health center POS, outpatient POS, or partial hospitalization POS and principal diagnosis of mental health or principal diagnosis of intentional self-harm with any diagnosis of mental health): CPT: 99495, 99496, 99381, 99382, 99381, 99382, 99392 Observation (with principal diagnosis of mental health or principal diagnosis of intentional self-harm with any diagnosis of mental health): CPT: 99495, 99496, 99381, 99382, 99391, 99392



Measure/coding tips	Measure description	Documentation required	Coding
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA)	The percentage of emergency department (ED) visits for members 13 years of age and older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence, who had a follow up visit for AOD. Two rates are reported: 1.The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days). 2. The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).	A follow-up visit with any practitioner, with a principal diagnosis of AOD within 30 days after the ED visit (31 total days). Includes visits that occur on the date of the ED visit. <b>Required exclusions:</b> Members who meet any of the following criteria are excluded from the measure: In hospice or using hospice services any time in the MY. <b>Optional exclusions:</b> Noncompliant members may be excluded from the measure with documentation of any of the following: • Deceased in the MY.	AOD abuse or dependence diagnosis: ICD-10: F10.10, F10.120, F10.121, F10.129, F10.130, F10.1 F10.130, F10.131, F10.132, F10.138, F10.19, F10.20, F10.23 F10.24, F10.239, F10.230, F10.231, F10.232, F10.239, F10.24, F10.280, F10.251, F10.259, F10.26, F10.27, F10.28 F10.281, F10.282, F10.288, F10.29, F11.10, F11.120, F11.120, F11.120, F11.120, F11.222, F11.229, F11.23, F11.24, F11.150, F11.120, F11.221, F11.222, F11.239, F11.28, F11.29, F12.10, F12.10, F12.120, F12.21, F12.22, F11.239, F12.13, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220, F12.221, F12.229, F12.23, F12.250, F12.251, F12.259, F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129, F13.11, F13.139, F13.130, F13.181, F13.182, F13.188, F13.19, F13.151, F13.139, F13.180, F13.181, F13.182, F13.288, F13.29, F13.26, F13.2 F13.280, F13.281, F13.282, F13.280, F13.231, F13.232, F13.280, F13.281, F13.282, F13.283, F13.29, F14.10, F14.1, F14.122, F14.122, F14.122, F14.229, F14.23, F14.428, F14.49, F14.141, F14.4150, F14.1124, F14.180, F14.181, F14.184, F14.180, F14.181, F14.422, F14.225, F14.229, F14.221, F14.222, F14.222, F14.228, F12.29, F15.23, F15.24, F15.28, F15.29, F15.20, F15.229, F15.23, F15.24, F15.220, F15.229, F15.23, F15.24, F15.220, F15.229, F15.23, F15.24, F15.20, F15.220, F15.229, F15.23, F15.24, F15.28, F15.29, F15.20, F15.220, F15.221, F15.229, F15.23, F15.24, F15.260, F15.251, F15.259, F15.20, F15.229, F15.23, F15.24, F15.28, F15.29, F15.20, F15.251, F15.259, F15.20, F15.229, F15.23, F15.24, F15.260, F15.251, F15.259, F15.250, F15.251, F15.259, F15.24, F15.28, F15.28, F15.29, F16.10, F16.120, F16.12, F16.120, F16.12, F16.129, F16.13, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.22, F16.229, F16.24, F16.250, F16.251, F16.250, F16.250, F16.250, F16.250, F16.251, F16.259, F15.251, F15.259, F15.251, F15.259, F15.251, F15.259, F15.251, F15.259, F15.24, F15.259, F15.24, F18.250, F18.251, F18.250, F18.251, F18.250, F18.251, F18.250, F18.27, F18.280, F18.29, F19.26, F19.271, F19.130, F19.131, F19.130



EFFECTIVENESS	EFFECTIVENESS OF CARE: BEHAVIORAL HEALTH		
Measure/coding tips	Coding		
Follow-Up After Emergency	OUD weekly drug treatment service (with a principal diagnosis of AOD abuse or dependence): HCPCS: G2067, G2068, G2069, G2070, G2072, G2073		
Department Visit for Alcohol and Other Drug Abuse or	IET visits group 1 (with IET POS group 1 and a principal diagnosis of AOD abuse or dependence): CPT: 90791, 90792, 90832, 90833, 90834, 90836, 90837, 90838, 90839, 90840, 90845, 90847, 90849, 90853, 90875, 90876		
Dependence (FUA) (Continued	<b>IET POS group 1:</b> <b>POS:</b> 02, 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 52, 53, 57, 58, 71, 72		
from page 10)	IET visits group 2 (with IET POS group 1 and a principal diagnosis of AOD abuse or dependence): CPT: 99221, 99222, 99223, 99231, 99232, 99233, 99238, 99239, 99251, 99252, 99253, 99254, 99255		
	IET POS group 2: POS: 02, 52, 53		
	Observation (with IET POS group 1 and a principal diagnosis of AOD abuse or dependence): CPT: 99217, 99218, 99219, 99220		
	Telephone visits (with IET POS group 1 and a principal diagnosis of AOD abuse or dependence): CPT: 98966, 98967, 98968, 99441, 99442, 99443		
	Online assessments (with IET POS group 1 and a principal diagnosis of AOD abuse or dependence): CPT: 98969, 98970, 98971, 98972, 98972, 99421, 99422, 99423, 99444, 99457, 99458 HCPCS: G0071, G2010, G2012, G2061, G2062, G2063		
	<b>Note:</b> LOINC and SNOMED codes can be captured through electronic data submissions. Please contact your Account Executive for more information.		



Moacuro /coding ting	Moacuro decerintien	Documentation required	Coding
Measure/coding tips	Measure description	Documentation required	Coding
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Members 13 years of age or older who had an acute inpatient hospitalization, residential treatment or detoxification visit for a diagnosis of substance use disorder that resulted in a follow- up visit or service for substance use disorder.	The percentage of acute inpatient hospitalizations, residential treatments, or detoxification visits for a diagnosis of substance use disorder among members 13 years of age and older that result in a follow-up visit or service for substance use disorder: Seven-day follow-up: A follow-up visit or event with any practitioner for a principal diagnosis of substance use disorder within the seven days after an episode for substance use disorder. <b>30</b> -day follow-up: A follow-up visit or event with any practitioner for a principal diagnosis of substance use disorder within the 30 days after an episode for substance use disorder. <b>Note:</b> • Methadone is not included in the medication lists for the measure. • Follow-up does not include detoxification. <b>Required exclusions:</b> Members who meet any of the following criteria are excluded from the measure: • In hospice or using hospice services any time in the MY. <b>Optional exclusions:</b> Noncompliant members may be excluded from the measure with documentation of any of the following: • Deceased in the MY.	AOD abuse or dependence diagnosis: ICD-10: F10.10, F10.120, F10.121, F10.129, F10.130, F10.13 F10.132, F10.139, F10.14, F10.150, F10.151, F10.159, F10.281, F10.229, F10.230, F10.231, F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280 F10.281, F10.282, F10.288, F10.29, F11.20, F11.120, F11.122 F11.122, F11.129, F11.13, F11.14, F11.150, F11.151, F11.152 F11.181, F11.182, F11.188, F11.19, F11.20, F11.227, F11.222 F11.222, F11.229, F11.23, F11.26, F12.20, F11.227, F11.225 F11.281, F11.282, F11.288, F11.29, F12.10, F12.120, F12.127, F12.229, F12.229, F12.23, F12.250, F12.251, F12.259, F12.250, F12.251, F12.259, F12.251, F12.259, F12.250, F12.251, F12.259, F12.251, F12.259, F12.251, F12.259, F12.251, F12.259, F12.251, F13.250, F13.251, F13.251, F14.251, F14.252, F14.262, F15.20, F15.221, F15.222, F15.222, F15.224, F15.20, F15.221, F15.224, F15.20, F15.221, F15.224, F15.20, F15.221, F15.222, F15.223, F15.24, F15.20, F15.221, F15.222, F15.222, F15.223, F15.224, F15.205, F15.251, F15.259, F15.272, F15.225, F15.225, F15.226, F15.221, F15.227, F15.222, F15.223, F15.224, F15.205, F15.251, F15.259, F15.272, F15.224, F15.252, F15.224, F15.252, F15.224, F15.252, F15.225, F15.225, F15.225, F15.225, F15.252,



Measure/coding tips	Coding			
Follow-Up After	IET POS group 1:			
High-Intensity Care for Substance Use		, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 52, 5 T POS Group 1 and a principal diagnosis of AOD abus		
Disorder (FUI)	011	3, 99231, 99232, 99233, 99238, 99239, 99251, 9925	, ,	
(Continued from page 12)	IET POS group 2: POS: 02, 52, 53			
from page 12)	Observation (with IET POS group 1 and a principal diagnosis of AOD abuse or dependence): CPT: 99217, 99218, 99219, 99220			
	Residential behavioral health treatment (with a principal diagnosis of AOD abuse or dependence): HCPCS: H0017, H0018, H0019, T2048			
	Telephone visits (with IET POS group 1 and a principal diagnosis of AOD abuse or dependence): CPT: 98966, 98967, 98968, 99441, 99442, 99443			
	Online assessments (with IET POS group 1 and a principal diagnosis of AOD abuse or dependence): CPT: 98969, 98970, 98971, 98972, 98972, 99421, 99422, 99423, 99444, 99457, 99458 HCPCS: G0071, G2010, G2012, G2061, G2062, G2063			
	AOD medication treatmen HPCPS: H0020, H0033, JC	n <b>t:</b> 1570, J0571, J0572, J0573, J0574, J0575, J2315, Q9	991, Q9992, S0109	
	OUD weekly drug treatment service:           HCPCS: G2067, G2068, G2070, G2072, G2073			
	Dispensing event of: Alcohol use disorder treatment medications: Aldehyde dehydrogenase inhibitor: disulfiram (oral) Antagonist: naltrexone (oral and injectable) Other: acamprosate (oral and delayed-release tablet)			
	Opioid use disorder treatment medications: Antagonist: naltrexone (oral and injectable) Partial agonist: buprenorphine (sublingual tablet, injection, implant), buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film)			
	<b>Note:</b> LOINC and SNOMEE more information.	codes can be captured through electronic data submi	ssions. Please contact your Account Executive for	
Measure/coding tips	Measure description	Documentation required	Coding	
Pharmacotherapy for Opioid Use Disorder (POD)	The percentage of new OUD pharmacotherapy events with OUD pharmacotherapy for 180 or more days among members age 16 and older with a diagnosis of OUD.	Intake period: 12-month period that begins on July 1 of the year prior to the MY and ends on June 30 of the MY. The treatment period (TP) is the date of an OUD dispensing event or OUD medication administration event during the IP. No more than an 8-day gap is allowed during the TP. <b>Note:</b> • Methadone is not included in the medication lists for the measure.	Antagonist: naltrexone (oral) Antagonist: naltrexone (injectable) Partial agonist: buprenorphine (sublingual tablet), buprenorphine (injection), buprenorphine (implant), buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) Agonist: methadone (oral) is only acceptable when billed on a medical claim. A pharmacy claim would be indicative of treatment for pain rather than OUD. Buprenorphine implant:	
		<ul> <li>Required exclusions: Members who meet any of the following criteria are excluded from the measure:</li> <li>In hospice or using hospice services any time in the MY.</li> <li>Optional exclusions: Noncompliant members may be excluded from the measure with documentation of any of the following:</li> <li>Deceased in the MY.</li> </ul>	HCPCS: G2070, G2072, J0570 Buprenorphine injection: HCPCS: G2069, Q9991, Q9992 Buprenorphine naloxone: HCPCS: J0572, J0573, J0574, J0575 Buprenorphine oral: HCPCS: J0571 Buprenorphine oral weekly: HCPCS: G2068, G2079 Methadone oral: HCPCS: H0020, H0033, S0109 Methadone oral weekly: HCPCS: G2067, G2078	



# www.amerihealthcaritasde.com